POROUS CELECOXIB MATRICES AND METHODS OF MANUFACTURE THEREOF

摘要

Celecoxib is provided in a porous matrix form wherein the dissolution rate o f the drug is enhanced when the matrix is contacted with an aqueous medium. Th e porous matrix yields upon contact with an aqueous medium nanoparticles and microparticles of celecoxib having a mean diameter between about 0.01 and 5 .mu.m and a total surface area greater than about 0.5 m2/mL. The dry porous matrix preferably is in a dry powder form having a TAP density less than or equal to 1.0 g/mL. The porous celecoxib matrices preferably are made using a process that includes: (i) dissolving celecoxib in a volatile solvent to for m a drug solution; (ii) combining at least one pore forming agent with the dru g solution to form an emulsion, suspension, or second solution; and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the dry porous matrix of celecoxib. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug.